STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #764 by analyst upside · 2026-06-27
GPCR
Structure Therapeutics Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+110.4%
implied upside to consensus target
Current Price $49.71
Consensus Target $104.59
Bull Target $145.0
Bear Target $69.5
Analysts Covering 16
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
11
Hold
1
Sell
0
52-Week Low $15.8
52-Week High $94.9
YTD Return -27.0%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E -25.7x
EPS (TTM) $-2.64
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $15.8
52-Week High $94.9
Current Price $49.71
Bear Target $69.5
Bull Target $145.0
● Now $49.71 ● Target $104.59
TRADING DATA
Avg Volume 883K
YTD Return -27.0%
Analyst Count 16
Consensus Buy
Upside to Target +110.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Structure Therapeutics Inc. (GPCR) is currently trading at $49.71 with a Wall Street consensus price target of $104.59, implying potential upside of 110.4% over the next 12 months. 16 analysts currently cover GPCR, with a consensus rating of Buy - 94% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $145.0, while the most cautious has a target of $69.5.

GPCR operates in the Healthcare sector with a market capitalisation of $4B. The stock is down 27.0% year-to-date and is currently trading near the lower end of its 52-week range of $15.8 – $94.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for GPCR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. — Reiterated
Buy → Buy 2026-06-11 31% win rate (48 calls)
Canaccord Genuity ● Initiated
Buy 2026-04-27 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-16 31% win rate (48 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-02 31% win rate (48 calls)
Citizens — Reiterated
Market Outperform → Market Outperform 2026-02-27 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-01-22 43% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2026-01-20 62% win rate (8 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2025-12-19 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
22/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →